VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | The role of venetoclax in the treatment of CLL

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the role of venetoclax in the treatment of chronic lymphocytic leukemia (CLL), highlighting its use in high- and low-risk patients, and the benefits of using venetoclax in combination with other agents such as BTK inhibitors and antibody therapies. Prof. Kater also talks on the reduced incidence of resistance observed when venetoclax is administered as a fixed-duration therapy and the role of venetoclax re-treatment. Finally, Prof. Kater outlines the frontline treatment landscape, commenting on the need to identify the optimal treatment regimens for different patient subgroups and the research underway in the CLL17 trial (NCT04608318), which is comparing ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Arnon Kater, MD, PhD, has participated in advisory boards and/or received research grants from Abbvie, BMS, Janssen, Roche/Genentech and Astra Zeneca; and has received speakers fees from Abbvie.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter